Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

55.81USD
16 Feb 2018
Change (% chg)

$0.02 (+0.04%)
Prev Close
$55.79
Open
$56.33
Day's High
$56.33
Day's Low
$55.31
Volume
19,247
Avg. Vol
36,078
52-wk High
$56.77
52-wk Low
$21.95

Chart for

About

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone... (more)

Overall

Beta: --
Market Cap(Mil.): $1,304.09
Shares Outstanding(Mil.): 36.37
Dividend: --
Yield (%): --

Financials

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

04 Jan 2018

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

21 Dec 2017

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

17 Nov 2017

BRIEF-Ascendis Pharma A/S prices public offering of 3.8 mln shares at $35.50 per ADS

* Ascendis Pharma A/S announces pricing of public offering of ADSs

27 Sep 2017

BRIEF-Ascendis Pharma A/S announces proposed public offering of ADSs

* Ascendis Pharma A/S announces proposed public offering of ADSs

27 Sep 2017

BRIEF-Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth

* Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth

26 Sep 2017

Competitors

Earnings vs. Estimates